OTLC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OTLC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Oncotelic Therapeutics's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Oncotelic Therapeutics's inventory stayed the same from Sep. 2023 to Dec. 2023 .
Oncotelic Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Oncotelic Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .
Oncotelic Therapeutics's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Oncotelic Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Oncotelic Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics (OTCPK:OTLC) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Oncotelic Therapeutics's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Oncotelic Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Oncotelic Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Oncotelic Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Vuong Trieu | officer: CHIEF EXECUTIVE OFFICER | 4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301 |
Saran Saund | officer: CHIEF BUSINESS OFFICER | C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301 |
Amit B. Shah | officer: CHIEF FINANCIAL OFFICER | 10 AGUILA, ALISO VIEJO CA 92656 |
Chulho Park | officer: CHIEF TECHNOLOGY OFFICER | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Maida Anthony E Iii | director | 157 TECHNOLOGY DR, IRVINE CA 92618 |
Steven W King | director | |
David Diamond | director | 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301 |
Fatih Uckun | 10 percent owner, officer: Chief Medical Officer | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Chao Hsiao | 10 percent owner | 701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080 |
Larn Hwang | 10 percent owner | C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748 |
Donald Rogers Reynolds | director | C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607 |
Sandage Bobby W Phd | director | C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173 |
Simon Pedder | director | 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203 |
Matthew M Loar | officer: Chief Financial Officer | 505 PENOBSCOT DR, REDWOOD CITY CA 94063 |
Pamela Ha | officer: Controller | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By sperokesalga sperokesalga • 06-12-2023
By Stock market mentor Stock market mentor • 01-25-2023
By Value_Insider Value_Insider • 11-16-2022
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 08-17-2022
By sperokesalga sperokesalga • 04-24-2023
By GuruFocusNews GuruFocusNews • 06-27-2022
By Marketwired • 08-23-2023
By sperokesalga sperokesalga • 04-17-2023
By PurpleRose PurpleRose • 08-22-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.